Cardlytics, Inc. (NASDAQ:CDLX) insider Kirk Somers sold 1,000 shares of the company’s stock in a transaction dated Thursday, January 13th. The shares were sold at an average price of $67.97, for a total value of $67,970.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.
Kirk Somers also recently made the following trade(s):
- On Wednesday, December 15th, Kirk Somers sold 1,000 shares of Cardlytics stock. The shares were sold at an average price of $66.26, for a total value of $66,260.00.
- On Friday, December 10th, Kirk Somers sold 7,241 shares of Cardlytics stock. The shares were sold at an average price of $68.56, for a total value of $496,442.96.
- On Friday, November 5th, Kirk Somers sold 11,468 shares of Cardlytics stock. The shares were sold at an average price of $91.46, for a total value of $1,048,863.28.
CDLX stock opened at $65.37 on Friday. The stock’s 50 day simple moving average is $70.13 and its 200 day simple moving average is $87.78. Cardlytics, Inc. has a fifty-two week low of $56.06 and a fifty-two week high of $161.47. The company has a quick ratio of 1.22, a current ratio of 1.22 and a debt-to-equity ratio of 0.26.
CDLX has been the topic of several research analyst reports. Zacks Investment Research upgraded Cardlytics from a “sell” rating to a “hold” rating in a research report on Tuesday, January 4th. Craig Hallum cut their target price on Cardlytics from $120.00 to $100.00 and set a “buy” rating on the stock in a research report on Wednesday, November 3rd. Three research analysts have rated the stock with a hold rating and three have given a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Buy” and an average target price of $126.14.
A number of hedge funds have recently bought and sold shares of the stock. FMR LLC raised its stake in Cardlytics by 2.3% during the 1st quarter. FMR LLC now owns 3,284,572 shares of the company’s stock worth $54,327,000 after buying an additional 72,847 shares during the period. Vanguard Group Inc. raised its stake in Cardlytics by 4.6% during the 2nd quarter. Vanguard Group Inc. now owns 2,861,557 shares of the company’s stock worth $363,217,000 after buying an additional 127,044 shares during the period. BlackRock Inc. raised its stake in shares of Cardlytics by 4.7% in the second quarter. BlackRock Inc. now owns 2,511,295 shares of the company’s stock worth $318,760,000 after purchasing an additional 111,838 shares during the last quarter. KPS Global Asset Management UK Ltd raised its stake in shares of Cardlytics by 10.3% in the second quarter. KPS Global Asset Management UK Ltd now owns 1,126,830 shares of the company’s stock worth $143,029,000 after purchasing an additional 105,000 shares during the last quarter. Finally, Morgan Stanley raised its stake in shares of Cardlytics by 24.1% in the third quarter. Morgan Stanley now owns 934,559 shares of the company’s stock worth $78,446,000 after purchasing an additional 181,266 shares during the last quarter. 93.50% of the stock is currently owned by institutional investors and hedge funds.
Cardlytics Company Profile
Cardlytics, Inc engages in the development of marketing solutions through its purchase intelligence platform. It operates through the Cardlytics Direct and Other Platform Solutions segments. The Cardlytics Direct segment represents its proprietary native bank advertising channel. The Other Platform Solutions segment includes solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel.
Featured Article: What Does a Sell-Side Analyst Rating Mean?
Receive News & Ratings for Cardlytics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardlytics and related companies with MarketBeat.com's FREE daily email newsletter.